3 completed, 1 active not recruiting, 1 unknown. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow SYN-004: new trials by email Literature Review of SYN-004 trials Research Report on SYN-004
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SYN-004 Safety and Tolerability in Allo-HCT Subjects SYN-004, Ribaxamase or Placebo - Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics | Phase 1 / Phase 2 | Active not recruiting | Theriva Biologics, Inc. | 36 | 2021-02-15 | 2026-03-17 |
| A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions SYN125, SYN004 - Epithelial Carcinoma, Solid Tumor | Phase 1 | Unknown | Synermore Biologics Co., Ltd. | 22 | 2020-04-09 | 2023-04-12 |
| A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI SYN-004, Placebo - Clostridium Difficile, Clostridium Infections | Phase 2 | Completed | Theriva Biologics, Inc. | 413 | 2015-10-01 | 2018-11-27 |
| A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy SYN-004, Esomeprazole, Ceftriaxone - Healthy Volunteers With Ileostomy | Phase 1 / Phase 2 | Completed | Theriva Biologics, Inc. | 15 | 2015-06-01 | 2018-11-27 |
| Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors SYN004 - Colon Cancer, Breast Cancer, Cancer of the Head and Neck | Phase 1 | Completed | Synermore Biologics Co., Ltd. | 10 | 2015-05-01 | 2018-11-16 |
Breast Neoplasms (1) · Carcinoma (1) · Clostridium Infections (1) · Colonic Neoplasms (1) · Head and Neck Neoplasms (1)
Theriva Biologics, Inc. (3) · Synermore Biologics Co., Ltd. (2)
United States (4) · Canada (2) · Bulgaria (1) · Hungary (1) · Poland (1) · Romania (1) · Serbia (1)
Ding Wang, MD (1) · John McClain, MD (1) · Michael Kaleko, MD (1)